A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Gastroesophageal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must ha e histologically or cytologically confirmed metastatic or recurrent gastric or GEJ adenocarcinoma. 2. Patients must have received and have progressed or are intolerant to at least one platinum- or fluoropyrimdine-based chemotherapy regimen for metastatic or recurrent disease. 3. Patients that are Her2 positive, must ha e received and have progressed or are intolerant to treatment with trastuzumab for metastatic or recurrent disease.

You may not be eligible for this study if the following are true:

  • 1. Prior anti-cancer monoclonal antibody treatment within 4 weeks prior to study 2. History of prior gastrointestinal fistula and/or perforation. 3. Brain metastases and/or carcinomatous meningitis, unless stable or evidence of active, non-infectious pneumonitis.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.